Literature DB >> 8550560

Hepatic overexpression of insulin-like growth factor-II in adulthood increases basal and insulin-stimulated glucose disposal in conscious mice.

L Rossetti1, N Barzilai, W Chen, T Harris, D Yang, C E Rogler.   

Abstract

The physiological role of circulating insulin-like growth factor-II (IGF-II) in adult humans is poorly understood. We recently generated an IGF-II transgenic murine model of persistent IGF-II production (plasma IGF-II approximately 30-fold increased above normal) through over-expression of the transgene driven by the major urinary protein promoter (Rinderknecht, E., and Humbel, R. E. (1978) J. Biol. Chem. 269, 13779-13784). To determine whether in vivo insulin action is improved in these transgenic mice, we performed euglycemic insulin (18 milliunits/kg.min) clamp studies in conscious IGF-II transgenic and in age- and weight-matched control mice. Plasma glucose and insulin concentrations were significantly lower in the IGF-II transgenic compared with both control grouoff Despite decreased plasma glucose concentration, basal hepatic glucose production (HGP) and glucose clearance were increased. During the insulin clamp studies in IGF-II transgenic mice compared with control mice (a) the rates of glucose infusion and glucose uptake were increased by approximately by 65 and approximately 55%, respectively; (b) glycolysis was increased by approximately 12% while glycogen synthesis was approximately 2-fold higher; (c) while the suppression of plasma free fatty acid was similar, the increment in plasma lactate concentration was significantly higher; (d) although HGP was similarly inhibited by insulin, phosphoenolpyruvate gluconeogenesis was enhanced and accounted for a larger portion of HGP (64% versus approximately 40% in control mice). Our data suggest that the persistence of circulating IGF-II in adult mice to levels commonly observed in adult humans (50-70 nM) causes a marked improvement in peripheral (skeletal muscle) insulin action, which is not due to changes in body composition. These results suggest that circulating IGF-II may exert a regulatory role on insulin sensitivity and body composition in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8550560     DOI: 10.1074/jbc.271.1.203

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor.

Authors:  Shouhong Xuan; Tadahiro Kitamura; Jun Nakae; Katerina Politi; Yoshiaki Kido; Peter E Fisher; Manrico Morroni; Saverio Cinti; Morris F White; Pedro L Herrera; Domenico Accili; Argiris Efstratiadis
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  Restoration of liver insulin signaling in Insr knockout mice fails to normalize hepatic insulin action.

Authors:  Haruka Okamoto; Silvana Obici; Domenico Accili; Luciano Rossetti
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

3.  Peripheral but not hepatic insulin resistance in mice with one disrupted allele of the glucose transporter type 4 (GLUT4) gene.

Authors:  L Rossetti; A E Stenbit; W Chen; M Hu; N Barzilai; E B Katz; M J Charron
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

Review 4.  Transcriptional regulation and biological significance of the insulin like growth factor II gene.

Authors:  W Engström; A Shokrai; K Otte; M Granérus; A Gessbo; P Bierke; A Madej; M Sjölund; A Ward
Journal:  Cell Prolif       Date:  1998 Oct-Dec       Impact factor: 6.831

5.  Uncoupling Exercise Bioenergetics From Systemic Metabolic Homeostasis by Conditional Inactivation of Baf60 in Skeletal Muscle.

Authors:  Zhuo-Xian Meng; Weiwei Tao; Jingxia Sun; Qiuyu Wang; Lin Mi; Jiandie D Lin
Journal:  Diabetes       Date:  2017-11-01       Impact factor: 9.461

6.  Cushing's syndrome and big IGF-II associated hypoglycaemia in a patient with adrenocortical carcinoma.

Authors:  Kazuhide Ishikura; Toshinari Takamura; Yumie Takeshita; Atsushi Nakagawa; Noriko Imaizumi; Hirofumi Misu; Komei Taji; Kazuo Kasahara; Yukinosuke Oshinoya; Shioto Suzuki; Akishi Ooi; Shuichi Kaneko
Journal:  BMJ Case Rep       Date:  2010-03-30

7.  Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type 2 diabetes.

Authors:  J C Devedjian; M George; A Casellas; A Pujol; J Visa; M Pelegrín; L Gros; F Bosch
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

8.  Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance.

Authors:  Roger Gutiérrez-Juárez; Alessandro Pocai; Claudia Mulas; Hiraku Ono; Sanjay Bhanot; Brett P Monia; Luciano Rossetti
Journal:  J Clin Invest       Date:  2006-06       Impact factor: 14.808

9.  Severe hypoglycemia associated with insulin-like growth factor II-producing liver metastasis from gastric carcinoma treated with overnight total parenteral nutrition via a central vein catheter reserve port.

Authors:  Yohei Koizumi; Atsushi Hiraoka; Kojiro Michitaka; Nayu Tazuya; Misa Ichiryu; Hiromasa Nakahara; Hironori Ochi; Atsushi Tanabe; Satoshi Hidaka; Akihiro Kodama; Takahide Uehara; Aki Hasebe; Yasunao Miyamoto; Tomoyuki Ninomiya; Teru Kumagi; Masanori Abe; Bunzo Matsuura; Norio Horiike; Yoichi Hiasa; Morikazu Onji
Journal:  Clin J Gastroenterol       Date:  2011-01-21

10.  Transgenic overexpression of insulin receptor substrate 1 in hepatocytes enhances hepatocellular proliferation in young mice only.

Authors:  Leonhard Mohr; Kakoli Banerjee; Manuela Kleinschmidt; María Matilde Bartolomé Rodríguez; Jack R Wands
Journal:  Hepatol Res       Date:  2008-07-04       Impact factor: 4.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.